Statistics for MSLs

Sorry, the event sold out.

About this event:

This Webinar will show participants how to interpret results from randomised clinical trials. Professor Allan Hackshaw will lead the training session.  He is Deputy Director, and Professor of Epidemiology & Medical Statistics at Cancer Research UK & UCL Cancer Trials Centre, one of the largest cancer trials units in the UK (please see a biography of Prof Allan Hackshaw below).

For those of you who have attended previous Conferences & Face-to-Face Stats training you will have had a taster of what to expect in this comprehensive short course.

Learning objectives: Course attendees will be able to –

  1. Understand the key principles of medical statistics
  2. To confidently interpret results from a statistical perspective
  3. Apply the learning from this session into own role

Pre-requisites: Attendees must be MSLA members

Elements that will come up during the session will include the following, depending on time & questions:-

  • Basics stats
  • Trials & sub-groups:
  • Brief outline of a randomised trial, and its key design strengths.
  • RWE
  • Measuring efficacy (effect sizes such as relative risk and hazard ratio), and understanding Kaplan-Meier curves.
  • Supporting statistics: 95% confidence intervals and properly understanding p-values (and how they are misinterpreted)
  • How can a treatment effect be both big and small?
  • Measuring safety/toxicity and drug adherence.

 Please register quickly to avoid disappointment. Places will be limited to 30 maximum and will be on a first come, first served basis.


Prof Allan Hackshaw

Allan Hackshaw is Professor of Epidemiology & Medical Statistics at University College London, and Deputy Director of the Cancer Research UK & UCL Cancer Trials Centre, one of the largest cancer trials units in the UK. He has >22 years’ experience in the design, conduct and interpretation of clinical trials, observational studies and systematic reviews, in a variety of disease areas (including cancer treatments, prognostic factors in cancer, antenatal & cancer screening; and tobacco and health). This has included major cohort/case-control studies, and phase II and large phase III trials.

He has been a key co-investigator on successful grant funding applications (~£56 million in total), and published 150 articles in journals and book chapters, plus sole or first author of four textbooks, including ‘A Concise Guide to Clinical Trials’ (Wiley/Blackwells). He is involved in postgraduate courses (on evidence-based medicine) at UCL, London School of Economics and Harvard. He has been a member of national and international scientific grant funding and data monitoring committees. In 2012 he was chosen as one of the top 40 academic role models in biomedicine at UCL.